Common Contracts

12 similar null contracts by ImmunoCellular Therapeutics, Ltd., Hall of Fame Resort & Entertainment Co, Intuitive Machines, Inc., others

SERIES H COMMON STOCK PURCHASE WARRANT HALL OF FAME RESORT & ENTERTAINMENT COMPANY
Hall of Fame Resort & Entertainment Co • March 25th, 2024 • Services-miscellaneous amusement & recreation • New York

THIS SERIES H COMMON STOCK PURCHASE WARRANT (the “Warrant”), dated as of February 6, 2024 (the “Warrant Date”), certifies that, for value received, HFAKOH001 LLC, a Delaware limited liability company (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date (as defined below), through and until 5:00 p.m. (New York City time) on the date which is three years after the Warrant Date (such date, the “Termination Date”), but not thereafter, to subscribe for and purchase from Hall of Fame Resort & Entertainment Company, a company incorporated under the laws of the State of Delaware (the “Company”), up to 890,313 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock (as defined in Section 1). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price (as defined in Section 2(b)). This Warrant shall be

AutoNDA by SimpleDocs
SERIES H COMMON STOCK PURCHASE WARRANT HALL OF FAME RESORT & ENTERTAINMENT COMPANY
Hall of Fame Resort & Entertainment Co • February 29th, 2024 • Services-miscellaneous amusement & recreation • New York

THIS SERIES H COMMON STOCK PURCHASE WARRANT (the “Warrant”), dated as of February 6, 2024 (the “Warrant Date”), certifies that, for value received, HFAKOH001 LLC, a Delaware limited liability company (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date (as defined below), through and until 5:00 p.m. (New York City time) on the date which is three years after the Warrant Date (such date, the “Termination Date”), but not thereafter, to subscribe for and purchase from Hall of Fame Resort & Entertainment Company, a company incorporated under the laws of the State of Delaware (the “Company”), up to 890,313 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock (as defined in Section 1). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price (as defined in Section 2(b)). This Warrant shall be

SERIES B COMMON STOCK PURCHASE WARRANT INTUITIVE MACHINES, INC.
Intuitive Machines, Inc. • January 30th, 2024 • Search, detection, navagation, guidance, aeronautical sys • New York

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Ghaffarian Enterprises, LLC, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July 29, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Intuitive Machines, Inc., a Delaware corporation (the “Company”), up to an aggregate of 4,150,780 shares (as subject to adjustment hereunder, the “Warrant Shares”) of, at the election of the Holder, the Company’s Class A common stock, par value $0.0001 per share (“Class A Common Stock”), the Company’s Class C common stock, par value $0.0001 per share (“Class C Common Stock” and, together with Class A Common Stock, “Common Stock”) or a combination thereof. The purchase price of one share of Common Stock under this Warra

SERIES A COMMON STOCK PURCHASE WARRANT INTUITIVE MACHINES, INC.
Intuitive Machines, Inc. • January 30th, 2024 • Search, detection, navagation, guidance, aeronautical sys • New York

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Ghaffarian Enterprises, LLC, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on January 29, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Intuitive Machines, Inc., a Delaware corporation (the “Company”), up to an aggregate of 4,150,780 shares (as subject to adjustment hereunder, the “Warrant Shares”) of, at the election of the Holder, the Company’s Class A common stock, par value $0.0001 per share (“Class A Common Stock”), the Company’s Class C common stock, par value $0.0001 per share (“Class C Common Stock” and, together with Class A Common Stock, “Common Stock”) or a combination thereof. The purchase price of one share of Common Stock under this Wa

AMENDED AND RESTATED COMMON STOCK PURCHASE WARRANT PASITHEA THERAPEUTICS CORP.
Pasithea Therapeutics Corp. • May 12th, 2023 • Pharmaceutical preparations

THIS AMENDED AND RESTATED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [____] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [____], 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Pasithea Therapeutics Corp., a Delaware corporation (the “Company”), up to [____] shares (as subject to adjustment hereunder, the “Warrant Shares”) of common stock of the Company (“Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

COMMON STOCK PURCHASE WARRANT Context Therapeutics Inc.
Context Therapeutics Inc. • May 11th, 2022 • Pharmaceutical preparations • New York

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ___________ (the “Termination Date”) but not thereafter, to subscribe for and purchase from Context Therapeutics Inc., a Delaware corporation (the “Company”), up to __________ shares of Common Stock (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

PRE-FUNDED COMMON STOCK PURCHASE WARRANT RETINALGENIX TECHNOLOGIES, INC.
RetinalGenix Technologies Inc. • December 30th, 2021 • Surgical & medical instruments & apparatus

THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Sanovas Ophthalmology, LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from RetinalGenix Technologies Inc., a Delaware corporation (the “Company”), up to 28,014,540 shares (as subject to adjustment hereunder, the “Warrant Shares” and together with the Warrant, the “Securities”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

SERIES A COMMON STOCK PURCHASE WARRANT PRESIDIO PROPERTY TRUST, INC.
Presidio Property Trust, Inc. • November 9th, 2021 • Real estate investment trusts • New York

THIS SERIES A COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date and on or prior to 5:00 p.m. (New York City time) on [ ]1, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from PRESIDIO PROPERTY TRUST, INC., a Maryland corporation (the “Company”), up to [ ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a Holder’s right to e

SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE WARRANT Akers Biosciences, Inc.
Akers Biosciences, Inc. • November 29th, 2019 • In vitro & in vivo diagnostic substances • New York

THIS SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the five (5) year anniversary of the date (the “Charter Amendment Date”) on which the Company (as defined below) publicly announces through the filing of a Current Report on Form 8-K that the amendment to the Company’s certificate of incorporation to sufficiently increase the Company’s authorized shares of Common Stock to cover the conversion of all then-outstanding shares of Preferred Stock into Common Stock has been filed with the Secretary of State of the State of New Jersey (the “Termination Date”)1 but not thereafter, to subscribe for and purchase from Akers Biosciences, Inc., a New Jerse

SERIES 2 PREFERRED STOCK WARRANT
ImmunoCellular Therapeutics, Ltd. • August 14th, 2017 • Pharmaceutical preparations • New York

THIS SERIES 2 WARRANT (the “Warrant”) certifies that, for value received, ________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. New York City time on January 22, 2018 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Company”), up to _______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Preferred Stock. The purchase price of one share of Preferred Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to (i) the Underwriting Agreement, dated as of July 18, 2017, between the Company and Maxim Group LLC (the “Underwriting Agreement”) and (ii) the Company’s Registration Statement on Form S-1 (File No.: 333

SERIES 3 PREFERRED STOCK WARRANT
ImmunoCellular Therapeutics, Ltd. • August 14th, 2017 • Pharmaceutical preparations • New York

THIS SERIES 3 WARRANT (the “Warrant”) certifies that, for value received, ________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. New York City time on July 23, 2018 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Company”), up to __________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Preferred Stock. The purchase price of one share of Preferred Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to (i) the Underwriting Agreement, dated as of July 18, 2017, between the Company and Maxim Group LLC (the “Underwriting Agreement”) and (ii) the Company’s Registration Statement on Form S-1 (File No.: 333

SERIES 1 PREFERRED STOCK WARRANT
ImmunoCellular Therapeutics, Ltd. • August 14th, 2017 • Pharmaceutical preparations • New York

THIS SERIES 1 WARRANT (the “Warrant”) certifies that, for value received, ________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. New York City time on October 23, 2017 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Company”), up to _________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Preferred Stock. The purchase price of one share of Preferred Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to (i) the Underwriting Agreement, dated as of July 18, 2017, between the Company and Maxim Group LLC (the “Underwriting Agreement”) and (ii) the Company’s Registration Statement on Form S-1 (File No.: 3

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!